Figure 5: TDO deficiency does not influence demyelination and clinical scores. | Scientific Reports

Figure 5: TDO deficiency does not influence demyelination and clinical scores.

From: Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis

Figure 5

(a) Representative Luxol-PAS stainings of spinal cord slides from WT and TDO−/− EAE mice sacrificed at the peak of disease. (b) Demyelinated area (counts) per slide. Mice were sacrificed on day 14 after immunization. At least 3 spinal cord slices of each mouse were analyzed, 6 mice per group. Statistical analysis was achieved by manual count of demyelinated lesions according to a demyelination score, Scale bars: 200 μm. (c,d) Clinical disease scores are shown from EAE mice (c) WT vs. TDO−/− with normal immunization protocol (MOG 200 μg/mouse), (d) WT vs. TDO−/− with low-dose immunization protocol (MOG 50 μg/mouse). Each panel shows one representative experiment out of at least three independent experiments. No statistically significant differences could be detected according to Mann-Whitney-U test.

Back to article page